These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582 [TBL] [Abstract][Full Text] [Related]
5. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A Antiviral Res; 2014 Sep; 109():7-14. PubMed ID: 24956496 [TBL] [Abstract][Full Text] [Related]
6. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J; J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372 [TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients. Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220 [TBL] [Abstract][Full Text] [Related]
8. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861 [TBL] [Abstract][Full Text] [Related]
9. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin]. Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759 [TBL] [Abstract][Full Text] [Related]
10. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484 [TBL] [Abstract][Full Text] [Related]
12. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960 [TBL] [Abstract][Full Text] [Related]
13. Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Ampuero J; Del Campo JA; Rojas L; Calleja JL; Cabezas J; Lens S; Crespo J; Forns X; Andrade RJ; Fernández I; Buti M; Millán R; Romero-Gómez M J Clin Virol; 2015 Jul; 68():56-60. PubMed ID: 26071337 [TBL] [Abstract][Full Text] [Related]
15. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]
16. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Burney T; Dusheiko G Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041 [TBL] [Abstract][Full Text] [Related]